why choose us

First received: October 18, 2022

Clinical Trial: A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Refractory Chronic Cough

Study Type: INTERVENTIONAL


Official Title: A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Incl

Brief Summary: This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Read more